Last Updated : August 28, 2024
Details
Generic Name:
semaglutide
Project Status:
Pending
Therapeutic Area:
Reduce the risk of major adverse cardiovascular events
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0841-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) and BMI equal to or greater than 27 kg/m2.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Anticipated: To reduce the risk of major adverse cardiovascular events
(cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in
adults with established cardiovascular disease (myocardial infarction, stroke
or peripheral arterial disease) and BMI equal to or greater than 27 kg/m2.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 28, 2024